MedTrace Logo

TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

NCT06513286 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2025-07-25

No results posted yet for this study

Summary

This study is an open-label, ascending dose phase 1b/2a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine in patients with chronic HBV who are virally suppressed with oral anti-viral therapies.

Conditions

Interventions

BIOLOGICAL

TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)

Administration of the described combinations via the intramuscular route

BIOLOGICAL

TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac)

Administration of the described combinations via the intramuscular route

Sponsors & Collaborators

  • Institute of Virology Helmholtz Zentrum München Trogerstraße 30 81675 Munich, Germany

    collaborator UNKNOWN

  • Michael Hoelscher

    lead OTHER

Principal Investigators

  • Michael Hoelscher, Prof. Dr. med. · Division of Infectious Diseases and Tropical Medicine, LMU Klinikum

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-12
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06513286 on ClinicalTrials.gov